These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 2499592

  • 1. A comparison of the suppressive effects of testosterone and a potent new gonadotropin-releasing hormone antagonist on gonadotropin and inhibin levels in normal men.
    Bagatell CJ, McLachlan RI, de Kretser DM, Burger HG, Vale WW, Rivier JE, Bremner WJ.
    J Clin Endocrinol Metab; 1989 Jul; 69(1):43-8. PubMed ID: 2499592
    [Abstract] [Full Text] [Related]

  • 2. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L, Bhasin S, Salameh W, Steiner B, Peterson M, Sokol RZ, Rivier J, Vale W, Swerdloff RS.
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [Abstract] [Full Text] [Related]

  • 3. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ, Matsumoto AM, Christensen RB, Rivier JE, Bremner WJ.
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [Abstract] [Full Text] [Related]

  • 4. Dose effects of the gonadotropin-releasing hormone antagonist, Nal-Glu, combined with testosterone enanthate on gonadotropin levels in normal men.
    Bagatell CJ, Rivier JE, Bremner WJ.
    Fertil Steril; 1995 Jul; 64(1):139-45. PubMed ID: 7789550
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men.
    Pavlou SN, Wakefield G, Schlechter NL, Lindner J, Souza KH, Kamilaris TC, Konidaris S, Rivier JE, Vale WW, Toglia M.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):446-54. PubMed ID: 2537334
    [Abstract] [Full Text] [Related]

  • 8. Hormonal responses to a potent gonadotropin hormone-releasing hormone antagonist in normal elderly men.
    Tenover JS, Dahl KD, Vale WW, Rivier JE, Bremner WJ.
    J Clin Endocrinol Metab; 1990 Oct; 71(4):881-8. PubMed ID: 2205625
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM.
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [Abstract] [Full Text] [Related]

  • 11. Persistence of concordant luteinizing hormone (LH), testosterone, and alpha-subunit pulses after LH-releasing hormone antagonist administration in normal men.
    Pavlou SN, Veldhuis JD, Lindner J, Souza KH, Urban RJ, Rivier JE, Vale WW, Stallard DJ.
    J Clin Endocrinol Metab; 1990 May; 70(5):1472-8. PubMed ID: 2110578
    [Abstract] [Full Text] [Related]

  • 12. Single subcutaneous doses of a luteinizing hormone-releasing hormone antagonist suppress serum gonadotropin and testosterone levels in normal men.
    Pavlou SN, Debold CR, Island DP, Wakefield G, Rivier J, Vale W, Rabin D.
    J Clin Endocrinol Metab; 1986 Aug; 63(2):303-8. PubMed ID: 3088019
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
    Swerdloff RS, Bagatell CJ, Wang C, Anawalt BD, Berman N, Steiner B, Bremner WJ.
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
    [Abstract] [Full Text] [Related]

  • 15. The importance of luteinizing hormone in the control of inhibin and progesterone secretion by the human corpus luteum.
    McLachlan RI, Cohen NL, Vale WW, Rivier JE, Burger HG, Bremner WJ, Soules MR.
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1078-85. PubMed ID: 2498381
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
    Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM.
    J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
    [Abstract] [Full Text] [Related]

  • 20. Marked suppression of gonadotropins and testosterone by an antagonist analog of gonadotropin-releasing hormone in men.
    Salameh W, Bhasin S, Steiner B, McAdams LA, Peterson M, Swerdloff R.
    Fertil Steril; 1991 Jan; 55(1):156-64. PubMed ID: 1898888
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.